BRPI0810093A2 - Promotor de formação de nevrite - Google Patents

Promotor de formação de nevrite

Info

Publication number
BRPI0810093A2
BRPI0810093A2 BRPI0810093-4A2A BRPI0810093A BRPI0810093A2 BR PI0810093 A2 BRPI0810093 A2 BR PI0810093A2 BR PI0810093 A BRPI0810093 A BR PI0810093A BR PI0810093 A2 BRPI0810093 A2 BR PI0810093A2
Authority
BR
Brazil
Prior art keywords
nevrite
formation promoter
promoter
formation
nevrite formation
Prior art date
Application number
BRPI0810093-4A2A
Other languages
English (en)
Inventor
Chiho Yabuta
Fumiko Yano
Mitsuyoshi Azuma
Original Assignee
Senju Pharma Co
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharma Co, Astellas Pharma Inc filed Critical Senju Pharma Co
Publication of BRPI0810093A2 publication Critical patent/BRPI0810093A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0810093-4A2A 2007-04-20 2008-04-18 Promotor de formação de nevrite BRPI0810093A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007112248 2007-04-20
PCT/JP2008/057583 WO2008133198A1 (ja) 2007-04-20 2008-04-18 神経突起形成促進剤

Publications (1)

Publication Number Publication Date
BRPI0810093A2 true BRPI0810093A2 (pt) 2014-10-21

Family

ID=39925652

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0810093-4A2A BRPI0810093A2 (pt) 2007-04-20 2008-04-18 Promotor de formação de nevrite

Country Status (11)

Country Link
US (1) US8637544B2 (pt)
EP (1) EP2157082B1 (pt)
JP (1) JP5179477B2 (pt)
KR (1) KR101486605B1 (pt)
CN (2) CN103251592B (pt)
BR (1) BRPI0810093A2 (pt)
CA (1) CA2684561C (pt)
ES (1) ES2577539T3 (pt)
MX (1) MX2009011250A (pt)
RU (1) RU2442582C2 (pt)
WO (1) WO2008133198A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6708630B2 (ja) * 2015-04-17 2020-06-10 国立大学法人 東京大学 角膜障害の予防又は治療剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP818099A0 (en) 1999-01-14 1999-02-11 Fujisawa Pharmaceutical Co., Ltd. New n-containing heterocyclic compounds
US6344358B1 (en) * 1999-05-28 2002-02-05 Fujisawa Pharmaceutical Co., Ltd. Agent for expression of long-term potentiation of synaptic transmission comprising compound having brain somatostatin activation property
ITRM20010755A1 (it) 2001-12-20 2003-06-20 Simonelli Giuseppe Uso del chinone q10 per il trattamento delle malattie oculari.
JPWO2003084542A1 (ja) * 2002-04-10 2005-08-11 藤沢薬品工業株式会社 神経栄養因子産生促進剤
JP4603976B2 (ja) * 2002-10-31 2010-12-22 千寿製薬株式会社 角膜障害治療剤
CN100413538C (zh) * 2002-10-31 2008-08-27 千寿制药株式会社 角膜疾病治疗剂
JP4453642B2 (ja) 2005-10-19 2010-04-21 日産自動車株式会社 駆動系の制振制御装置
EP1991212A1 (en) 2006-03-08 2008-11-19 Braincells, Inc. Modulation of neurogenesis by nootropic agents

Also Published As

Publication number Publication date
RU2009142843A (ru) 2011-05-27
KR101486605B1 (ko) 2015-01-26
US20100144792A1 (en) 2010-06-10
JPWO2008133198A1 (ja) 2010-07-22
US8637544B2 (en) 2014-01-28
RU2442582C2 (ru) 2012-02-20
KR20090130142A (ko) 2009-12-17
EP2157082B1 (en) 2016-06-08
CN101687795B (zh) 2013-05-08
CN101687795A (zh) 2010-03-31
MX2009011250A (es) 2009-11-05
WO2008133198A1 (ja) 2008-11-06
EP2157082A4 (en) 2011-03-30
CA2684561A1 (en) 2008-11-06
ES2577539T3 (es) 2016-07-15
EP2157082A1 (en) 2010-02-24
JP5179477B2 (ja) 2013-04-10
CA2684561C (en) 2015-06-30
CN103251592B (zh) 2015-07-29
CN103251592A (zh) 2013-08-21

Similar Documents

Publication Publication Date Title
NO2021036I1 (no) Ofatumumab
NL300788I2 (nl) Pembrolizumab
ATE542825T1 (de) Substituierte piperidino-dihydrothienopyrimidine
DK2354233T5 (da) Patogen inducerbar syntetisk promotor
BRPI0821573A2 (pt) benzofuropirimidonas
ATE514696T1 (de) Diphenyl-dihydro-imidazopyridinone
BRPI0811451A2 (pt) Exopolissacarídeo
BRPI0814519A2 (pt) Organopolissiloxano
BRPI0812840A2 (pt) 2-imidazolinas
FI20075851A0 (fi) Muodostusosa
AT505058A3 (de) Türschliesssystem
BRPI0815547A2 (pt) Depsipeptídeos cícliocos
BRPI0812994A2 (pt) Microbiocidas
BRPI0816334A2 (pt) Corrimão modificado
DE112008001216A5 (de) Magnetronplasmaanlage
BRPI0922716A2 (pt) purificação de polipeptídeo
BRPI0806971A2 (pt) Promotores induzíveis pela deficiência de água
DE112008003094A5 (de) Geomatte
DE112008002200A5 (de) Sperrsynchronisiervorrichtung
CU20090155A7 (es) Macrolidos
DK2195435T3 (da) Trichoderma-promoter
DE102007038931A8 (de) Fadenlagennähwirkstoffe
FI20086106A (fi) Nastarenkaan nasta
DE502008002040D1 (de) Fahrzeughilfsrahmen
BRPI0810093A2 (pt) Promotor de formação de nevrite

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25G Requested change of headquarter approved

Owner name: SENJU PHARMACEUTICAL CO. LTD. (JP) ; ASTELLAS PHAR

Owner name: SENJU PHARMACEUTICAL CO. LTD. (JP) ; ASTELLAS PHARMA INC (JP)

B09B Patent application refused [chapter 9.2 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]